Jitendra Singh reviews BRIC-inStem trials, including first-in-human haemophilia gene therapy
Union Minister Dr. Jitendra Singh visited BRIC-inStem, Bengaluru, and reviewed its clinical trials, including the first-in-human gene therapy trial for haemophilia conducted with CMC Vellore, as reported on 24 April 2025.
Summary
Union Minister of State (Independent Charge) for Science and Technology Dr. Jitendra Singh inspected facilities at BRIC-inStem in Bengaluru and reviewed ongoing clinical trials with medical institutes and hospitals, including the first-in-human gene therapy trial for haemophilia conducted with CMC Vellore, which he called a milestone in India's scientific journey. He said India's biotechnology sector has grown 16-fold in the past decade to $165.7 billion in 2024, with a vision of $300 billion by 2030, and credited policy reforms including the BIO-E3 Policy.
Key facts
- Institute
- BRIC-inStem, Bengaluru
- Trial
- First-in-human gene therapy for haemophilia, with CMC Vellore
- Bioeconomy
- $165.7 billion in 2024 (16-fold in a decade); vision $300 billion by 2030
- Policy cited
- BIO-E3 Policy
Practice MCQs 2 questions
With which institution was the first-in-human gene therapy trial for haemophilia, reviewed at BRIC-inStem, conducted?
Show answer
Correct answer: D — CMC Vellore
The first-in-human gene therapy trial for haemophilia was conducted with CMC Vellore.
According to Dr. Jitendra Singh, what was the size of India's biotechnology sector in 2024?
Show answer
Correct answer: B — $165.7 billion
India's biotechnology sector reached $165.7 billion in 2024; $300 billion is the 2030 vision.